STAAR Surgical Co (STAA) - התחייבויות לטווח ארוך להון

Cash flows for STAAR Surgical Company (STAA) are moderately resilient, as demand for elective vision correction depends on consumer purchasing power. The business relies on expansion in the Asia-Pacific region and the global rise of myopia. The share price history, where the indicator stands at 0.09, confirms the company's status as a stable asset due to the integration of patented lenses into clinic surgical standards and strong physician loyalty to the product.

This indicator measures the proportion of long-term debt obligations relative to equity, allowing for an assessment of financial stability and the company's degree of dependence on external borrowed financing. In-house production of Collamer biomaterial minimizes operational risks, which, combined with the long-term debt structure ratio, confirms the high autonomy of STAAR Surgical Company (STAA) and the strength of its fundamental position.